Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Daiichi Sankyo Co., Ltd.
  6. News
  7. Summary
    4568   JP3475350009

DAIICHI SANKYO CO., LTD.

(4568)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about DAIICHI SANKYO CO., LTD.
03/20Daiichi Sankyo - Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity ..
AQ
03/19Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patie..
BU
03/14Transcript : Daiichi Sankyo Company, Limited - Special Call
CI
03/07ENHERTU (fam-trastuzumab deruxtecan-nxki) showed clinically meaningful and durable resp..
AQ
03/06Enhertu showed clinically meaningful and durable responses across multiple HER2-express..
AQ
03/06ENHERTU« Showed Clinically Meaningful and Durable Responses Across Multiple HER2 Expres..
BU
03/06Astrazeneca and Daiichi Sankyo's Enhertu Met Prespecified Criteria for Objective Respon..
CI
03/06Daiichi Sankyo Announces ENHERTU Showed Clinically Meaningful and Durable Responses Acr..
CI
02/20Daiichi Sankyo Co., Ltd. - U.S. Patent Office Re-Institutes Post Grant Review of Seagen..
AQ
02/16U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between ..
BU
02/01TURALIO« New Dosing Regimen Now Available in the U.S. for Certain Patients with Tenosyn..
BU
02/01Daiichi Sankyo Company, Limited Announces New Dosing Regimen for TURALIO Now Available ..
CI
01/31Daiichi Sankyo Posts 8% Decline in Fiscal Nine-month Attributable Profit on Growing Exp..
MT
01/31Transcript : Daiichi Sankyo Company, Limited, Q3 2023 Earnings Call, Jan 31, ..
CI
01/31Daiichi Sankyo Company, Limited Appoints Hiroyuki Okuzawa as New President & COO Effect..
CI
More most relevant news
All news about DAIICHI SANKYO CO., LTD.
03/20Zymeworks Terminates Research, Development, Commercialization Agreement with Daiichi Sa..
MT
03/20Daiichi Sankyo - Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity ..
AQ
03/19Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patie..
BU
03/16Sector Update: Health Care Stocks Add to Midday Advance
MT
03/16Top Midday Decliners
MT
03/16Sector Update: Health Care Stocks Carried Higher in Rebounding Thursday Ma..
MT
03/16Credit Suisse Lifeline, Data Prompt Cautious Premarket Trading for US Equity Futures
MT
03/16Esperion Therapeutics in Disagreement With Partner Over Cholesterol Drug Milestone Paym..
MT
03/16Top Premarket Decliners
MT
03/14Transcript : Daiichi Sankyo Company, Limited - Special Call
CI
More news
News in other languages on DAIICHI SANKYO CO., LTD.
03/20Zymeworks met fin à l'accord de recherche, de développement et de commercialisation ave..
03/16Mise à jour sectorielle : Les actions du secteur de la santé pro..
03/16Principales baisses en milieu de journée
03/16Sector Update : Les actions du secteur de la santé sont portées par le reb..
03/16Credit Suisse Lifeline, les données incitent à la prudence pour les contrats à terme su..
03/16Esperion Therapeutics en désaccord avec un partenaire sur les paiements d'étape pour un..
03/16Principales baisses avant bourse
03/13Pfizer übernimmt Krebsspezialisten für 43 Milliarden Dollar
03/12Grünen-Fraktionschefin verteidigt Atomausstieg als Sicherheitsgewinn
03/12Grünen-Fraktionschefin verteidigt Atomausstieg als Sicherheitsgewinn
More news
Analyst Recommendations on DAIICHI SANKYO CO., LTD.
2022Jefferies Adjusts Daiichi Sankyo's Price Target to 5,300 Yen From 4,300 Yen, Keeps at B..
MT
2022MarketScreener's World Press Review : June 6, 2022
MS
2019AstraZeneca raises sales forecast after second quarter cancer drug, China boost
RE
More recommendations
Press releases
03/20Daiichi Sankyo - Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity ..
AQ
03/19Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patie..
BU
03/07ENHERTU (fam-trastuzumab deruxtecan-nxki) showed clinically meaningful and durable resp..
AQ
03/06Enhertu showed clinically meaningful and durable responses across multiple HER2-express..
AQ
03/06ENHERTU« Showed Clinically Meaningful and Durable Responses Across Multiple HER2 Expres..
BU
More press releases
Upcoming event on DAIICHI SANKYO CO., LTD.
1 MarketScreener is worth more than 1000 Influencers!
100% Free Registration
fermer